Empirical Application of the Sentinel Electronic Health Record (EHR) and Claims Data Partner Network to Address ARIA Insufficient Inferential Requests Read more about Empirical Application of the Sentinel Electronic Health Record (EHR) and Claims Data Partner Network to Address ARIA Insufficient Inferential Requests
Neupogen (Filgrastim), Remicade (Infliximab), and Neulasta (Pegfilgrastim) & Biosimilar Use Read more about Neupogen (filgrastim), Remicade (infliximab), and Neulasta (pegfilgrastim)
An R Package to Perform Routine Structural Missing Data Investigations in Real-World Data Read more about An R Package to Perform Routine Structural Missing Data Investigations in Real-World Data
Characterizing Missing Data Processes in EHR Data Read more about Characterizing Missing Data Processes in EHR Data
SMDI: An R Package to Perform Routine Structural Missing Data Investigations in Real-World Data Read more about SMDI: An R Package to Perform Routine Structural Missing Data Investigations in Real-World Data
Non-Cardiac Congenital Malformations Algorithm Defined in "Risk of Non-Cardiac Congenital Malformations Following Armodafinil or Modafinil Use: A Propensity Score Matched Analysis" Read more about Non-Cardiac Congenital Malformations Algorithm Defined in "Risk of Non-Cardiac Congenital Malformations Following Armodafinil or Modafinil Use: A Propensity Score Matched Analysis"
Risk of Non-Cardiac Congenital Malformations Following Armodafinil or Modafinil Use: A Propensity Score Matched Analysis Read more about Risk of Non-Cardiac Congenital Malformations Following Armodafinil or Modafinil Use: A Propensity Score Matched Analysis
Unexpected Issues in Pharmacoepidemiology Studies Applying Natural Language Processing to Clinical Notes Read more about Unexpected Issues in Pharmacoepidemiology Studies Applying Natural Language Processing to Clinical Notes
Characterization of COVID-19 Vaccination Data in the SDD Read more about Characterization of COVID-19 Vaccination Data in the SDD
Utilization of Guselkumab, Risankizumab, Tildrakizumab, and Brodalumab: Second Descriptive Analysis Read more about Utilization of Guselkumab, Risankizumab, Tildrakizumab, and Brodalumab: Second Descriptive Analysis